EA202191323A1 - Применение 3-о-сульфамата 16,16-диметил-d-гомоэквиленина для лечения онкологических заболеваний - Google Patents
Применение 3-о-сульфамата 16,16-диметил-d-гомоэквиленина для лечения онкологических заболеванийInfo
- Publication number
- EA202191323A1 EA202191323A1 EA202191323A EA202191323A EA202191323A1 EA 202191323 A1 EA202191323 A1 EA 202191323A1 EA 202191323 A EA202191323 A EA 202191323A EA 202191323 A EA202191323 A EA 202191323A EA 202191323 A1 EA202191323 A1 EA 202191323A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- homoequilenin
- sulfamate
- dimethyl
- treatment
- cancer
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000000771 oncological effect Effects 0.000 title abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 abstract 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 238000009098 adjuvant therapy Methods 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 208000010749 gastric carcinoma Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 238000009097 single-agent therapy Methods 0.000 abstract 1
- 201000000498 stomach carcinoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение относится к области медицины и химико-фармацевтической промышленности и касается средств для лечения рака. 3-O-сульфамат-16,16-диметил-D-гомоэквиленина предложен в качестве противоонкологического агента при моно- и адъювантной терапии при онкологических заболеваниях, таких как гепатокарцинома, карцинома желудка, рак легкого, хроническая миелогенная лейкемия, рак молочной железы, включая трижды негативную форму рака молочной железы.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2018139336A RU2680603C1 (ru) | 2018-11-08 | 2018-11-08 | Применение 3-о-сульфамата-16,16-диметил-d-гомоэквиленина для лечения онкологических заболеваний |
PCT/RU2019/000650 WO2020096486A1 (ru) | 2018-11-08 | 2019-09-19 | Применение 3-о-сульфамата 16,16-диметил-d-гомоэквиленина для лечения онкологических заболеваний |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202191323A1 true EA202191323A1 (ru) | 2021-08-06 |
Family
ID=65479433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202191323A EA202191323A1 (ru) | 2018-11-08 | 2019-09-19 | Применение 3-о-сульфамата 16,16-диметил-d-гомоэквиленина для лечения онкологических заболеваний |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220105058A1 (ru) |
EP (1) | EP3878454A4 (ru) |
CN (1) | CN113507932A (ru) |
EA (1) | EA202191323A1 (ru) |
RU (1) | RU2680603C1 (ru) |
WO (1) | WO2020096486A1 (ru) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2755250C1 (ru) * | 2021-01-21 | 2021-09-14 | Ильясова Наталья Эдуардовна | Препарат на основе стероидных эстрогенов для лечения эндометриоза |
RU2752064C1 (ru) * | 2021-02-02 | 2021-07-22 | Ильясова Наталья Эдуардовна | Новый способ синтеза 3-о-сульфамата 16,16-диметил-d-гомоэквиленина |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001005415A2 (en) * | 1999-07-15 | 2001-01-25 | Københavns Universitet | Composition having steroidal estrogen effect without increasing the risk of breast cancer |
DE10307103A1 (de) * | 2003-02-19 | 2004-09-09 | Schering Ag | Antitumor wirksame 2-substituierte D-Homostra-1,3,5(10)-trien-3-yl sulfamate |
CN101129353B (zh) * | 2007-09-17 | 2010-04-14 | 北京珅奥基医药科技有限公司 | 7-羟基-3-[(4-羟基)-3-(3-甲基-丁基-2-烯基)苯基]-4h-1-苯并吡喃-4-酮的用途 |
CN101199509B (zh) * | 2007-10-31 | 2010-11-03 | 北京珅奥基医药科技有限公司 | 2",2"-二甲基-2"h,4h-3,6"-二苯并吡喃-4-酮在制备抗肿瘤药物中的用途 |
KR101819544B1 (ko) * | 2016-11-25 | 2018-01-17 | 애니젠 주식회사 | 5'-하이드록시-5-니트로-인디루빈-3'-옥심을 유효 성분으로 함유하는 유방암 치료제 |
-
2018
- 2018-11-08 RU RU2018139336A patent/RU2680603C1/ru active
-
2019
- 2019-09-19 WO PCT/RU2019/000650 patent/WO2020096486A1/ru unknown
- 2019-09-19 EA EA202191323A patent/EA202191323A1/ru unknown
- 2019-09-19 EP EP19882497.1A patent/EP3878454A4/en active Pending
- 2019-09-19 CN CN201980088362.1A patent/CN113507932A/zh active Pending
- 2019-09-19 US US17/292,688 patent/US20220105058A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220105058A1 (en) | 2022-04-07 |
WO2020096486A1 (ru) | 2020-05-14 |
CN113507932A (zh) | 2021-10-15 |
EP3878454A1 (en) | 2021-09-15 |
EP3878454A4 (en) | 2022-08-24 |
RU2680603C1 (ru) | 2019-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122566T1 (el) | Παραγωγο 6,7,8,9-tetpaϋδpo-3h-πυραζολo[4,3-f] ισοκινολινης χρησιμο στη θεραπευτικη αντιμετωπιση του καρκινου | |
MX2020008777A (es) | Inmunoterapias relacionadas con el microbioma. | |
EA201890146A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
NZ752526A (en) | Pyrrolobenzodiazepine conjugates | |
WO2016161342A3 (en) | Nitrobenzyl derivatives of anti-cancer agents | |
EA201791516A1 (ru) | Способы комбинированного лечения злокачественных опухолей | |
EA201650134A1 (ru) | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором | |
EA201890009A1 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
BR112015019064A8 (pt) | uso de uma composição compreendendo nanopartículas compreendendo paclitaxel e uma albumina para o tratamento de melanoma e kit | |
EA201990951A1 (ru) | Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение | |
MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
MX2016016744A (es) | Inhibidores de ezh2 para tratar linfomas. | |
EA201690608A1 (ru) | Способы лечения раковых заболеваний | |
MX2023000796A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
EA201892834A1 (ru) | Комбинированная химиотерапия | |
EA201891514A1 (ru) | Комбинированная терапия ингибитором бромодомена и экстратерминального белка | |
EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
MX2019003694A (es) | Metodos para tratar cancer del tracto biliar. | |
EA202191323A1 (ru) | Применение 3-о-сульфамата 16,16-диметил-d-гомоэквиленина для лечения онкологических заболеваний | |
EA202191170A1 (ru) | Комбинированная терапия для лечения гематологических заболеваний | |
EP3991749A3 (en) | A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody | |
MX2022011372A (es) | Composiciones de zinc-y-pga y metodos para tratar el cancer. | |
MX2019002047A (es) | Metodos y composiciones para tratar infecciones fungicas cutaneas. | |
EA201792256A1 (ru) | Соли и пролекарства 1-метил-d-триптофана | |
PH12020500096A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor |